Evolving concepts in the management of drug resistant ovarian cancer: Dose dense chemotherapy and the reversal of clinical platinum resistance

摘要: Despite the initially high response rate to standard front-line debulking surgery followed by platinum-based chemotherapy, relapse in ovarian cancer is and many patients will recur within 6 months of completing platinum based treatment. These may still require further chemotherapy despite being considered “platinum resistant”. In this setting, rates conventionally scheduled second line non-platinum agents low, ranging between 5% 15%. There an emerging body evidence that scenario, chemotherapeutic activity can be enhanced using unconventionally “dose-dense” regimens with improved up 65%. Randomised studies evaluate impact approach on survival recurrent, resistant disease are urgently required confirm promising phase II findings if there a change care disease. review we discuss evolving strategies overcome resistance particular focus alterations dose schedule as means reversing resistance.